User profiles for Michael P. Menden
 | Michael P. MendenAssociate Professor, University of Melbourne, Department of Biochemistry and … Verified email at helmholtz-muenchen.de Cited by 5784 |
[PDF][PDF] A landscape of pharmacogenomic interactions in cancer
Systematic studies of cancer genomes have provided unprecedented insights into the
molecular nature of cancer. Using this information to guide the development and application of …
molecular nature of cancer. Using this information to guide the development and application of …
A community effort to assess and improve drug sensitivity prediction algorithms
Predicting the best treatment strategy from genomic information is a core goal of precision
medicine. Here we focus on predicting drug response based on a cohort of genomic, …
medicine. Here we focus on predicting drug response based on a cohort of genomic, …
[HTML][HTML] Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties
Predicting the response of a specific cancer to a therapy is a major goal in modern oncology
that should ultimately lead to a personalised treatment. High-throughput screenings of …
that should ultimately lead to a personalised treatment. High-throughput screenings of …
A community computational challenge to predict the activity of pairs of compounds
Recent therapeutic successes have renewed interest in drug combinations, but experimental
screening approaches are costly and often identify only small numbers of synergistic …
screening approaches are costly and often identify only small numbers of synergistic …
[HTML][HTML] Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen
The effectiveness of most cancer targeted therapies is short-lived. Tumors often develop
resistance that might be overcome with drug combinations. However, the number of possible …
resistance that might be overcome with drug combinations. However, the number of possible …
[HTML][HTML] Prediction of human population responses to toxic compounds by a collaborative competition
The ability to computationally predict the effects of toxic compounds on humans could help
address the deficiencies of current chemical safety testing. Here, we report the results from a …
address the deficiencies of current chemical safety testing. Here, we report the results from a …
Artificial intelligence in early drug discovery enabling precision medicine
Introduction: Precision medicine is the concept of treating diseases based on environmental
factors, lifestyles, and molecular profiles of patients. This approach has been found to …
factors, lifestyles, and molecular profiles of patients. This approach has been found to …
[HTML][HTML] Machine learning and pharmacometrics for prediction of pharmacokinetic data: differences, similarities and challenges illustrated with rifampicin
Pharmacometrics (PM) and machine learning (ML) are both valuable for drug development
to characterize pharmacokinetics (PK) and pharmacodynamics (PD). Pharmacokinetic/…
to characterize pharmacokinetics (PK) and pharmacodynamics (PD). Pharmacokinetic/…
Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls
… Author links open overlay panel Anna HC Vlot 1 2 , Natália Aniceto 1 , Michael P. Menden 3
… to S WSS,BLISS (P = 3.8%), S WSS,HSA (P = 7.0%), and S WSS,ZIP (P = 9.6%). This does …
… to S WSS,BLISS (P = 3.8%), S WSS,HSA (P = 7.0%), and S WSS,ZIP (P = 9.6%). This does …
[HTML][HTML] The oncology biomarker discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer
Precision medicine has revolutionised cancer treatments; however, actionable biomarkers
remain scarce. To address this, we develop the Oncology Biomarker Discovery (OncoBird) …
remain scarce. To address this, we develop the Oncology Biomarker Discovery (OncoBird) …